Department of Nuclear Medicine, The Fourth Clinical Medical College of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.
Harbin Orthopedics Hospital, Harbin, Heilongjiang 150080, P.R. China.
Mol Med Rep. 2018 Feb;17(2):2137-2144. doi: 10.3892/mmr.2017.8154. Epub 2017 Nov 27.
The current study observed the percentage of peripheral blood (PB) CD4+CD25+ regulatory T cells (Tregs) and the influence of CD4+CD25+ Tregs on the proliferation of naïve CD4 T cells in patients with hyperthyroidism. Furthermore, preliminary discussions are presented on the action mechanism of CD4+CD25+ Tregs on hyperthyroidism attacks. The present study identified that compared with the percentage of PB CD4+CD25+ Tregs in healthy control subjects, no significant changes were observed in the percentage of PB CD4+CD25+ Tregs in patients with hyperthyroidism (P>0.05). For patients with hyperthyroidism, CD4+CD25+ Tregs exhibited significantly reduced inhibition of the proliferation of naïve CD4 T cells and decreased secretion capacity on the cytokines of CD4 T cells, compared with those of healthy control subjects (P<0.05). In addition, it was demonstrated that thyroid function of patients with hyperthyroidism was significantly improved (P<0.05) subsequent to receiving medication. Compared with the percentage of PB CD4+CD25+ Tregs in patients with hyperthyroidism before treatment, no significant changes were observed in the percentage of PB CD4+CD25+ Tregs in hyperthyroidism patients following treatment (P>0.05). In the patients with hyperthyroidism, following treatment, CD4+CD25+ Tregs exhibited significantly increased inhibition of the proliferation of naïve CD4 T cells and increased secretion capacity of CD4 T cell cytokines, compared with those of the patients with hyperthyroidism prior to treatment (P<0.05). PB CD4+CD25+ Tregs function was decreased in patients with hyperthyroidism, and its non‑proportional decrease may be closely associated with the occurrence and progression of hyperthyroidism.
本研究观察了甲状腺功能亢进症患者外周血（PB）CD4+CD25+调节性 T 细胞（Tregs）的百分比，以及 CD4+CD25+Tregs 对幼稚 CD4 T 细胞增殖的影响。此外，还初步探讨了 CD4+CD25+Tregs 对甲状腺功能亢进症发作的作用机制。本研究发现，与健康对照组 PB CD4+CD25+Tregs 的百分比相比，甲状腺功能亢进症患者 PB CD4+CD25+Tregs 的百分比无明显变化（P＞0.05）。对于甲状腺功能亢进症患者，与健康对照组相比，CD4+CD25+Tregs 对幼稚 CD4 T 细胞增殖的抑制作用明显降低，对 CD4 T 细胞细胞因子的分泌能力也降低（P＜0.05）。此外，还表明甲状腺功能亢进症患者的甲状腺功能在接受药物治疗后明显改善（P＜0.05）。与治疗前甲状腺功能亢进症患者 PB CD4+CD25+Tregs 的百分比相比，治疗后甲状腺功能亢进症患者 PB CD4+CD25+Tregs 的百分比无明显变化（P＞0.05）。在甲状腺功能亢进症患者中，治疗后，与治疗前的甲状腺功能亢进症患者相比，CD4+CD25+Tregs 对幼稚 CD4 T 细胞增殖的抑制作用明显增强，CD4 T 细胞细胞因子的分泌能力也增强（P＜0.05）。甲状腺功能亢进症患者 PB CD4+CD25+Tregs 功能降低，其非比例降低可能与甲状腺功能亢进症的发生和发展密切相关。
